Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated May 2026 · ClinicalTrials.gov

Xijing Hospital

9 clinical trials · 9 recruiting · OTHER

Xijing Hospital has 9 clinical trials registered on ClinicalTrials.gov, with 9 actively recruiting participants. The trials listed below cover 20 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About Xijing Hospital\'s Trial Portfolio

Xijing Hospital is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

9 of Xijing Hospital's 9 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

Xijing Hospital's research footprint spans Gastric Cancer (1 trials), precancerous-lesion-of-digestive-tract (1), and extrachromosomal-dna (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

is the largest single phase in Xijing Hospital's portfolio at 56% of registered trials. The full phase breakdown appears in the sidebar.

Trials by Xijing Hospital

RECRUITINGNCT05956847

The Role of Extracellular DNA (ecDNA) in the Occurrence and Development of Gastric

ECDNA is almost non-existent in normal cells, but exists in nearly half of human cancer cells, indicating that studying such abnormal DNA is of great significance for our...

Sponsor: Xijing HospitalEnrolling: 10001 location
Gastric CancerPrecancerous Lesion of Digestive TractExtrachromosomal DNA
RECRUITINGNCT01372800

Serum Adiponectin in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases

Adiponectin (Ad) is an abundant protein in human body, and reports have shown that it act as a novel risk factor for brain and heart ischemia injury. This 5 years follow-up study...

Sponsor: Xijing HospitalEnrolling: 300001 location
Myocardial InfarctionCerebral Infarction
RECRUITINGNCT05353140

LAAO Versus NOAC in Patients with AF and PCI

Atrial fibrillation (AF) coincides with coronary artery disease (CAD) shared common risk factors and pathophysiologic pathways. CAD affects approximately 25% of AF patient...

Sponsor: Xijing HospitalEnrolling: 13861 location
Atrial FibrillationPercutaneous Coronary Intervention
RECRUITINGNCT07180368

Assessment and Management of Multiple Drug Use in Elderly Chronic Disease Patients

The purpose of this observational study is to understand the impact of polypharmacy on the prognosis of elderly patients with chronic diseases. The main research question it aims...

Sponsor: Xijing HospitalEnrolling: 20001 location
Coronary Artery DiseaseDiabete MellitusChronic Kidney Disease+6
RECRUITINGNCT06379386

Long-term Prognosis and Valve Durability of TAVR

This registry aims to evaluate the long-term prognosis and valve durability of transcatheter aortic valve replacement (TAVR) in a real-world setting. Baseline characteristics,...

Sponsor: Xijing HospitalEnrolling: 10001 location
Aortic Valve Stenosis and Insufficiency
RECRUITINGNCT06830499

Sapien 3 Transcatheter Aortic Valve Replacement in Young Aortic Valve Stenosis Patients From China

Safety, effectiveness and durability of Sapien 3 transcatheter aortic valve replacement in young aortic valve stenosis patients from China:A multi-center, retrospective and...

Sponsor: Xijing HospitalEnrolling: 4504 locations
AORTIC VALVE DISEASESBicuspid Aortic Valve (BAV)
RECRUITINGNCT07114159

Long-term Safety and Efficacy of Sacral Nerve Stimulation in Patients With Ulcerative Colitis

Although the incidence of inflammatory bowel disease is stable in North American and European countries, the incidence of inflammatory bowel disease is increasing in newly...

Sponsor: Xijing HospitalEnrolling: 151 location
Ulcerative Colitis
RECRUITINGNCT07270003

A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the...

What's the problem? Palmoplantar pustulosis (PPP) is a long-term skin condition that mainly affects the palms of hands and soles of feet. It causes red, scaly skin with small,...

Sponsor: Xijing HospitalEnrolling: 601 location
Palmoplantar Pustulosis (PPP)
RECRUITINGNCT07552454

Picankibart in Palmoplantar Pustulosis

1. Study Design This study is designed as a prospective, single-arm, open-label clinical study. It will be conducted by the Department of Dermatology, the First Affiliated...

Sponsor: Xijing HospitalEnrolling: 601 location
Palmoplantar Pustulosis

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does Xijing Hospital have on ClinicalTrials.gov?

Xijing Hospital has 9 clinical trials registered on the federal ClinicalTrials.gov registry, of which 9 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does Xijing Hospital study?

Xijing Hospital's registered trials cover 20 conditions on ClinicalTrials.gov, led by Gastric Cancer (1 trial), precancerous-lesion-of-digestive-tract (1 trial), extrachromosomal-dna (1 trial), Myocardial Infarction (1 trial), Cerebral Infarction (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a Xijing Hospital clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-05-08 · 9 trials tracked for Xijing Hospital.

For this entity, the underlying data on this page comes from the NIH ClinicalTrials.gov registry. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.

Every number on this page links back to the NIH ClinicalTrials.gov registry; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within active and historical clinical trials. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.